Category Archives: Jim’s Corner

Patient groups join call for data protection

Biomedical innovation is not only key to our industry’s future, but more importantly, continued medical breakthroughs are vital to patients living with debilitating diseases and their families. Without ongoing progress in our industry, patients of today and tomorrow have limited hope for future cures and therapies. Many patient groups have entered the debate on Capitol Hill over establishing a pathway for approval of biosimilars because they know how critical continued innovation is to finding new Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

Victory on Biosimilars in Senate HELP Committee – But Still a Long Way from the Finish Line

Last evening the Senate Health, Education, Labor and Pensions (HELP) Committee adopted an amendment to the healthcare reform package that provided 12 years of data exclusivity for innovative biologics. This event was a significant victory for our companies and for patients. Two and a half years ago Senator Clinton and Congressman Waxman introduced bills that provided zero years of data exclusivity. Following extensive negotiations, Senators Kennedy, Enzi, Hatch, Schumer and Clinton agreed to a bill Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

The Washington Post: Special section on biotechnology

As part of our public education/industry branding campaign, BIO sponsored a special section on biotechnology which ran in The Washington Post on Wednesday, June 24: http://ukpublic.mediaplanet.com/biotechwashpostfinal.pdf The insert provides a general introduction to biotech, emphasizing how biotechnology is helping to heal, feed and fuel the world.  We also used the piece to disseminate some of our key messages surrounding biosimilars. The special section was included in the 713,000 printed copies of the Post distributed in Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

Health Reform Debate Heats Up and Slows Down

The health reform debate is heating up and, in at least one respect, slowing down a bit. On Sunday, President Obama, PhRMA and the Senate Finance Committee announced an agreement to help close the coverage gap in the Medicare prescription drug program to help reduce the cost of comprehensive health-reform.  Under the proposal, U.S. drug companies would provide half-price discounts to Medicare recipients in the “doughnut hole” and provide other unspecified discounts and rebates for Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

Already Looking Ahead to BIO 2010 in Chicago

The whirlwind of the BIO 2009 International Convention has come to a close. For the first time in a week I’m not rushing, racing, talking or being interviewed. I thought the Convention was a huge success and that’s what everyone who offered me their opinions seemed to be saying. Despite the economic recession, we had well over 14,000 attendees. The Business Forum was humming with something like 15,000 one-on-one meetings. For me it started last Read More >

Jim's Corner  |  Leave a comment  |  Email This Post